array:5 [
  "content-type" => array:1 [
    0 => "text/html; charset=UTF-8"
  ]
  "cache-control" => array:1 [
    0 => "no-cache, private"
  ]
  "date" => array:1 [
    0 => "Thu, 26 Dec 2024 18:23:41 GMT"
  ]
  "set-cookie" => array:2 [
    0 => "XSRF-TOKEN=eyJpdiI6IncxaHdvM1Uyb01ydE0wbFdXNithc1E9PSIsInZhbHVlIjoicFJrNldZVmlYRXkrVVd1eElOU1Bqa2dsVEIzR2F1RVEzaXhSYnVwQS8wTXdxUnV3QzF3N3NKajd5T3ZFM1hZZ3pRVDB4OFY0ZGp0aVcxNjBmTFhnSHE3bCtYVjVlTWI4RURFdnVxUVRqYnJLYmFIUEJ0UWU5SlpXeXRpaTVSTGEiLCJtYWMiOiI0MDVhMmFlZTU2ZTM1Nzc2MjRjNzAxOGY0MGU0MGViMzU3YWVjMDc0NGUzNzgyNTY0M2QzOWY4NjdiMGJkYTRiIiwidGFnIjoiIn0%3D; expires=Sun, 29 Dec 2024 06:23:41 GMT; Max-Age=216000; path=/; secure; samesite=strict"
    1 => "eurekaselectnew_session=eyJpdiI6IjVVVEFkMVR5VktIWUNsTmRNdVNlYmc9PSIsInZhbHVlIjoiUllEWVhpeXlPSm4zMlpYbXBQdUwwU3lIMnRvbGxmSlFmQ0l4bHltb0ZCL2pnRkkzNVRqeGNOcGZoNHc0bFNOR2I5MXljaWNBcHFZVG1ydzd4dko1MCtIc201ZGp2QTBpN0lZbkhZbnFURkpuSWNoQ1Z4V1p6VkNDNGY5eTUwK1UiLCJtYWMiOiIzNDJhMzc4NzZiYjE2M2E1OTA0YTc1ZDdjY2QzYzk3ZWFiZDg5NjEyZWU4MGRiMTcxMzk2YzYzY2FhYTE2ZjlhIiwidGFnIjoiIn0%3D; path=/; secure; httponly; samesite=strict"
  ]
  "Set-Cookie" => array:2 [
    0 => "XSRF-TOKEN=eyJpdiI6IncxaHdvM1Uyb01ydE0wbFdXNithc1E9PSIsInZhbHVlIjoicFJrNldZVmlYRXkrVVd1eElOU1Bqa2dsVEIzR2F1RVEzaXhSYnVwQS8wTXdxUnV3QzF3N3NKajd5T3ZFM1hZZ3pRVDB4OFY0ZGp0aVcxNjBmTFhnSHE3bCtYVjVlTWI4RURFdnVxUVRqYnJLYmFIUEJ0UWU5SlpXeXRpaTVSTGEiLCJtYWMiOiI0MDVhMmFlZTU2ZTM1Nzc2MjRjNzAxOGY0MGU0MGViMzU3YWVjMDc0NGUzNzgyNTY0M2QzOWY4NjdiMGJkYTRiIiwidGFnIjoiIn0%3D; expires=Sun, 29-Dec-2024 06:23:41 GMT; path=/; secure"
    1 => "eurekaselectnew_session=eyJpdiI6IjVVVEFkMVR5VktIWUNsTmRNdVNlYmc9PSIsInZhbHVlIjoiUllEWVhpeXlPSm4zMlpYbXBQdUwwU3lIMnRvbGxmSlFmQ0l4bHltb0ZCL2pnRkkzNVRqeGNOcGZoNHc0bFNOR2I5MXljaWNBcHFZVG1ydzd4dko1MCtIc201ZGp2QTBpN0lZbkhZbnFURkpuSWNoQ1Z4V1p6VkNDNGY5eTUwK1UiLCJtYWMiOiIzNDJhMzc4NzZiYjE2M2E1OTA0YTc1ZDdjY2QzYzk3ZWFiZDg5NjEyZWU4MGRiMTcxMzk2YzYzY2FhYTE2ZjlhIiwidGFnIjoiIn0%3D; path=/; secure; httponly"
  ]
]
Search Result "HE<sub>CrossMAb</sub>."

An Anti-EGFR/anti- HER2 Bispecific Antibody with Enhanced Antitumor Activity Against Acquired Gefitinib-Resistant NSCLC Cells

Apply Filters

Content Type
